ewsba.se
Written by Sarah Sidlow for The Motley Fool->
Chief Strategy and Business Officer Atul Dandekar exercised and sold 7,500 shares of common stock for a transaction value of ~$190,000 on April 29, 2026.
This represented 41.66% of Dandekar's direct common stock holdings, reducing direct ownership from 18,000 to 10,503 shares.
The transaction was derivative-driven, involving option exercise and immediate sale; no indirect holdings were involved.
Dandekar retains 44,143 stock options (direct), which can be converted to common stock for future liquidity.
Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics (NASDAQ:MAZE), reported the exercise and immediate sale of 7,500 shares of common stock for a transaction value of approximately $190,000 on April 29, 2026, as disclosed in this SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($25.37); post-transaction value based on April 29, 2026, market close ($25.68).
1-year price change calculated using April 29, 2026, as the reference date.
Maze Therapeutics, Inc. is a clinical-stage biotechnology company leveraging genetic insights to develop targeted therapies for complex renal and metabolic diseases. The company’s strategy centers on advancing a focused pipeline of oral small-molecule drugs with the potential to address significant unmet medical needs. With a lean workforce and a strong emphasis on precision medicine, Maze Therapeutics seeks to differentiate itself through innovation and a data-driven approach to drug development.
Following insider transactions can be a useful way to gauge what’s going on with a company, but there are limitations to that approach. Dandekar netted nearly $200,000 from his April 29 share sale, but the transaction was an exercise-and-sell maneuver that was pursuant to a Rule 10b5-1 trading plan. That’s a trading tool available for company insiders that allows them to buy or sell shares on a predetermined schedule, so as to avoid the appearance of insider trading. While the move was lucrative, with Maze stock up nearly 200% year over year at the time of the transaction, it shouldn’t signal anything specific to investors about Dandekar’s conviction in the company’s prospects.
March was a big month for the clinical-stage biotech. It reported fourth-quarter and full-year 2025 earnings results on March 25, highlighting positive top-line data from its phase 2 Horizon trial of MZE829 and $360 million in cash, cash equivalents, and marketable securities on the balance sheet, which management projects should give the company a cash runway into 2028. It expects to initiate two phase 2 proof-of-concept clinical trials for MZA782 later this year.
Shares of small-cap clinical-stage healthcare companies like Maze can swing dramatically on good or bad clinical trial results, highlighting both the opportunity and the risk inherent in investing in the space. The stock received two price target raises in March, according to Insider Monkey. On March 25, H.C. Wainwright raised its price target to $110 from $60 and maintained a buy rating, highlighting MZE829’s Horizon trial data and “best-in-class” profile. On March 31, J.P. Morgan raised its price target to $58 from $52.
Before you buy stock in Maze Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Maze Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $473,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,204,650!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 7, 2026.
Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This data feed is not available at this time.